MarketBeat
Arrowhead Pharmaceuticals Teases 2026 Catalysts, Waylivra Launch Momentum at TD Cowen Conference
📈
AI Sentiment
Highly Positive
8/10
- Home
- ARWR
as of 03-11-2026 3:44pm EST
$58.19
$1.02
-1.71%
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 10.1B | IPO Year: | 2009 |
| Target Price: | $81.50 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.22 | EPS Growth: | 99.80 |
| 52 Week Low/High: | $10.65 - $76.76 | Next Earning Date: | 05-08-2026 |
| Revenue: | $16,142,321 | Revenue Growth: | -48.60% |
| Revenue Growth (this year): | -43.99% | Revenue Growth (next year): | -29.43% |
| P/E Ratio: | 269.95 | Index: | N/A |
| Free Cash Flow: | 156.9M | FCF Growth: | N/A |
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
Hamilton James C
Sell
Chief Medical Officer
ARWR Mar 5, 2026
Avg Cost/Share
$64.19
Shares
10,000
Total Value
$641,900.00
Owned After
236,958
SEC Form 4
Hamilton James C
Sell
Chief Medical Officer
ARWR Jan 5, 2026
Avg Cost/Share
$64.13
Shares
40,164
Total Value
$2,534,661.46
Owned After
236,958
O'Brien Patrick
Sell
COO
ARWR Jan 5, 2026
Avg Cost/Share
$63.92
Shares
49,493
Total Value
$3,123,349.43
Owned After
484,976
Anzalone Christopher Richard
Sell
Chief Executive Officer
ARWR Jan 2, 2026
Avg Cost/Share
$66.13
Shares
13,187
Total Value
$871,702.77
Owned After
3,798,510
Anzalone Christopher Richard
Sell
Chief Executive Officer
ARWR Dec 29, 2025
Avg Cost/Share
$69.01
Shares
51,726
Total Value
$3,575,574.78
Owned After
3,798,510
Ferrari Mauro
Sell
Director
ARWR Dec 26, 2025
Avg Cost/Share
$70.00
Shares
7,530
Total Value
$527,100.00
Owned After
69,053
SEC Form 4
Anzalone Christopher Richard
Sell
Chief Executive Officer
ARWR Dec 22, 2025
Avg Cost/Share
$68.59
Shares
12,586
Total Value
$861,339.86
Owned After
3,798,510
Waddill William D.
Sell
Director
ARWR Dec 19, 2025
Avg Cost/Share
$67.73
Shares
8,367
Total Value
$566,038.07
Owned After
56,563
Anzalone Christopher Richard
Sell
Chief Executive Officer
ARWR Dec 19, 2025
Avg Cost/Share
$67.72
Shares
13,445
Total Value
$909,682.52
Owned After
3,798,510
Vakiener Victoria
Sell
Director
ARWR Dec 19, 2025
Avg Cost/Share
$67.66
Shares
10,040
Total Value
$679,491.34
Owned After
37,683
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hamilton James C | ARWR | Chief Medical Officer | Mar 5, 2026 | Sell | $64.19 | 10,000 | $641,900.00 | 236,958 | |
| Hamilton James C | ARWR | Chief Medical Officer | Jan 5, 2026 | Sell | $64.13 | 40,164 | $2,534,661.46 | 236,958 | |
| O'Brien Patrick | ARWR | COO | Jan 5, 2026 | Sell | $63.92 | 49,493 | $3,123,349.43 | 484,976 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Jan 2, 2026 | Sell | $66.13 | 13,187 | $871,702.77 | 3,798,510 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 29, 2025 | Sell | $69.01 | 51,726 | $3,575,574.78 | 3,798,510 | |
| Ferrari Mauro | ARWR | Director | Dec 26, 2025 | Sell | $70.00 | 7,530 | $527,100.00 | 69,053 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 22, 2025 | Sell | $68.59 | 12,586 | $861,339.86 | 3,798,510 | |
| Waddill William D. | ARWR | Director | Dec 19, 2025 | Sell | $67.73 | 8,367 | $566,038.07 | 56,563 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Dec 19, 2025 | Sell | $67.72 | 13,445 | $909,682.52 | 3,798,510 | |
| Vakiener Victoria | ARWR | Director | Dec 19, 2025 | Sell | $67.66 | 10,040 | $679,491.34 | 37,683 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 5, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 5, 2026 · 100% conf.
AI Prediction SELL
1D
-8.34%
$59.25
Act: -0.99%
5D
-7.68%
$59.68
Act: -3.57%
20D
-2.11%
$63.27
Act: -7.82%
Price: $64.64 Prob +5D: 0% AUC: 1.000
0000879407-26-000033
arwr-202602050000879407FALSE00008794072026-02-052026-02-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
February 5, 2026 Date of Report (Date of earliest event reported)
Arrowhead Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3804246-0408024 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105 (Address of principal executive offices, including Zip Code) (626) 304-3400 (Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On February 5, 2026, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2026 financial results for the period ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press Release, dated February 5, 2026.
104Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: February 5, 2026
ARROWHEAD PHARMACEUTICALS, INC.
By:/s/ Daniel Apel Daniel Apel Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 25, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 25, 2025
0000879407-25-000027
arwr-202511250000879407FALSE00008794072025-11-252025-11-25
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
November 25, 2025 Date of Report (Date of earliest event reported)
Arrowhead Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3804246-0408024 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105 (Address of principal executive offices, including Zip Code) (626) 304-3400 (Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On November 25, 2025, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2025 financial results for the period ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press Release, dated November 25, 2025.
104Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: November 25, 2025
ARROWHEAD PHARMACEUTICALS, INC.
By:/s/ Daniel Apel Daniel Apel Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 7, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 7, 2025
0001628280-25-038867
arwr-202508070000879407FALSE00008794072025-08-072025-08-07
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934
August 7, 2025 Date of Report (Date of earliest event reported)
Arrowhead Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3804246-0408024 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105 (Address of principal executive offices, including Zip Code) (626) 304-3400 (Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ARWR The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition On August 7, 2025, Arrowhead Pharmaceuticals, Inc. announced and commented on its fiscal 2025 financial results for the period ended March 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.Description
99.1Press Release, dated August 7, 2025.
104Cover Page Interactive Data File (the cover page tags are embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: August 7, 2025
ARROWHEAD PHARMACEUTICALS, INC.
By:/s/ Daniel Apel Daniel Apel Chief Financial Officer
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
Compare ARWR vs Leading Stocks
See how ARWR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.